Remdesivir is being prescribed under FDA emergency use authorization as a treatment for patients with COVID-19.
List view / Grid view
Filter the results
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Scientists have identified a new family of biosynthetic genes in lichens with unknown functions, which could produce new molecules for the pharmaceutical industry.
Dr Diogo Camacho from the Wyss Institute at Harvard discusses new research into using machine learning algorithms to analyse RNA sequences and reveal potential drug targets.
Chinese hamster ovary (CHO) cell lines are a firm favourite with biologics companies because of the extensive developmental work undertaken in recent decades. In this article, Junrui Li divulges how CRISPR technology is now being employed to further enhance productivity.
Glycosaminoglycans (GAGs) are a class of naturally occurring polysaccharides that play vital roles in cellular functions. GAGs (eg, hyaluronic acid, heparosan, chondroitin, chondroitin sulfate, heparan sulfate and heparin) have also been utilised in biopharmaceutical and nutraceutical industries. Animal-sourced GAGs can contain process impurities and contaminants, which may result in adverse…
When it comes to developing antibody drugs, Dr Jerome Boyd-Kirkup and his team are not sticking to the classical playbook. Here, he explains how they use systems biology and immuno-engineering to remove the element of luck from biologic drug discovery and development.
The Vi-CELL BLU automates the widely accepted trypan blue dye exclusion method for cell viability that has historically been performed with a light microscope, pipette, and a hemacytometer.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.